A prospective evaluation of the effect of finasteride on prostate health index (phi)
Purpose 5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index ( phi ) is unknown. This study aims to investigate this effect and to enable accurate interpretation of phi in men with elevated PSA and on 5ARI. Methods This is a prosp...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2023-05, Vol.55 (5), p.1087-1092 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1092 |
|---|---|
| container_issue | 5 |
| container_start_page | 1087 |
| container_title | International urology and nephrology |
| container_volume | 55 |
| creator | Chiu, Peter Ka-Fung Chan, Chun-Hong Liu, Alex Qinyang Lau, Sui-Yan Leung, Chi-Ho Chan, Yun-Sang Yuen, Steffi Kar-Kei Yee, Chi-Hang Teoh, Jeremy Yuen-Chun Tang, Wai-Lun Poon, Wing-Tat Ng, Chi-Fai |
| description | Purpose
5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index (
phi
) is unknown. This study aims to investigate this effect and to enable accurate interpretation of
phi
in men with elevated PSA and on 5ARI.
Methods
This is a prospective study evaluating the effect of finasteride on PSA, free PSA (fPSA), [ – 2]proPSA (p2PSA) and
phi
at 6 and 12 moths in men with PSA 4-20 ng/mL, no prior 5ARI use, and one negative prostate biopsy within 6 months before recruitment. The 5ARI Finasteride (5 mg/day) for 1 year was offered if International Prostatic Symptom Score (IPSS) was ≥ 8 at baseline. 5ARI group included patients taking finasteride, while control group included patients not on finasteride. The blood results were compared with
t
-test between baseline and different time points in each group and between groups at 1 year.
Results
164 men fit the inclusion criteria and 150 were analyzed. In 5ARI group (n = 100) at 1 year, mean PSA reduced by 51.4% from 8.9(± SD 3.7) to 4.4(± SD 2.8)ng/mL (paired t-test, p |
| doi_str_mv | 10.1007/s11255-023-03530-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2781214267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2781214267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-29748cf1770e5f610d073ef2e67ca5ceaaf00d41ee12b5c7b1f0b0ae635951d53</originalsourceid><addsrcrecordid>eNp9kDtPwzAUhS0EoqXwBxhQJJYyBK7tOE7HquIlVWIps-Uk1yRVmoTYqeDf45LyEAOTH-c7x9eHkHMK1xRA3lhKmRAhMB4CFxxCfkDGVEgeMpFEh7_2I3Ji7RoAZgnAMRnxOBHxjIkxWc2Dtmtsi5krtxjgVle9dmVTB40JXOFvjPHa7mTKWluHXZlj4PWdzWmHQYG6ckVQ1jm-BdO2KK9OyZHRlcWz_Tohz3e3q8VDuHy6f1zMl2HGpXAhm8koyQyVElCYmEIOkqNhGMtMiwy1NgB5RBEpS0UmU2ogBY0xFzNBc8EnZDrk-llee7RObUqbYVXpGpveKiYTymjEYunRyz_ouum72k-nWAI0gogz5ik2UJn_nO3QqLYrN7p7VxTUrnM1dK585-qzc8W96WIf3acbzL8tXyV7gA-A9VL9gt3P2__EfgBGY4tn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2801404322</pqid></control><display><type>article</type><title>A prospective evaluation of the effect of finasteride on prostate health index (phi)</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Chiu, Peter Ka-Fung ; Chan, Chun-Hong ; Liu, Alex Qinyang ; Lau, Sui-Yan ; Leung, Chi-Ho ; Chan, Yun-Sang ; Yuen, Steffi Kar-Kei ; Yee, Chi-Hang ; Teoh, Jeremy Yuen-Chun ; Tang, Wai-Lun ; Poon, Wing-Tat ; Ng, Chi-Fai</creator><creatorcontrib>Chiu, Peter Ka-Fung ; Chan, Chun-Hong ; Liu, Alex Qinyang ; Lau, Sui-Yan ; Leung, Chi-Ho ; Chan, Yun-Sang ; Yuen, Steffi Kar-Kei ; Yee, Chi-Hang ; Teoh, Jeremy Yuen-Chun ; Tang, Wai-Lun ; Poon, Wing-Tat ; Ng, Chi-Fai</creatorcontrib><description>Purpose
5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index (
phi
) is unknown. This study aims to investigate this effect and to enable accurate interpretation of
phi
in men with elevated PSA and on 5ARI.
Methods
This is a prospective study evaluating the effect of finasteride on PSA, free PSA (fPSA), [ – 2]proPSA (p2PSA) and
phi
at 6 and 12 moths in men with PSA 4-20 ng/mL, no prior 5ARI use, and one negative prostate biopsy within 6 months before recruitment. The 5ARI Finasteride (5 mg/day) for 1 year was offered if International Prostatic Symptom Score (IPSS) was ≥ 8 at baseline. 5ARI group included patients taking finasteride, while control group included patients not on finasteride. The blood results were compared with
t
-test between baseline and different time points in each group and between groups at 1 year.
Results
164 men fit the inclusion criteria and 150 were analyzed. In 5ARI group (n = 100) at 1 year, mean PSA reduced by 51.4% from 8.9(± SD 3.7) to 4.4(± SD 2.8)ng/mL (paired t-test, p < 0.001), fPSA reduced by 52.4% from 1.6(± 0.6) to 0.8(± 0.4)ng/mL (p < 0.001), p2PSA reduced by 55.3% from 18.4(± 8.8) to 8.3(± 5.6)pg/mL (p < 0.001), and
phi
reduced by 34.2% from 33.7(± 11.9) to 22.4(± 12.5) (p < 0.001). PSA and
phi
values in the control group remained static over 1 year and significantly higher than those in 5ARI group.
Conclusion
This study demonstrated p2PSA and phi are reduced by about 55% and 34% in men on 5ARI. A conversion factor of division by 0.66 is needed for
phi
in men on finasteride to allow the interpretation and use of
phi
in men on 5ARI.</description><identifier>ISSN: 1573-2584</identifier><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1007/s11255-023-03530-3</identifier><identifier>PMID: 36856925</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biopsy ; Finasteride - pharmacology ; Finasteride - therapeutic use ; Humans ; Male ; Medicine ; Medicine & Public Health ; Nephrology ; Prospective Studies ; Prostate ; Prostate - pathology ; Prostate cancer ; Prostate-Specific Antigen ; Prostatic Neoplasms - pathology ; Urology ; Urology - Original Paper</subject><ispartof>International urology and nephrology, 2023-05, Vol.55 (5), p.1087-1092</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Nature B.V.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-29748cf1770e5f610d073ef2e67ca5ceaaf00d41ee12b5c7b1f0b0ae635951d53</citedby><cites>FETCH-LOGICAL-c375t-29748cf1770e5f610d073ef2e67ca5ceaaf00d41ee12b5c7b1f0b0ae635951d53</cites><orcidid>0000-0003-0302-0472</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11255-023-03530-3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11255-023-03530-3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36856925$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chiu, Peter Ka-Fung</creatorcontrib><creatorcontrib>Chan, Chun-Hong</creatorcontrib><creatorcontrib>Liu, Alex Qinyang</creatorcontrib><creatorcontrib>Lau, Sui-Yan</creatorcontrib><creatorcontrib>Leung, Chi-Ho</creatorcontrib><creatorcontrib>Chan, Yun-Sang</creatorcontrib><creatorcontrib>Yuen, Steffi Kar-Kei</creatorcontrib><creatorcontrib>Yee, Chi-Hang</creatorcontrib><creatorcontrib>Teoh, Jeremy Yuen-Chun</creatorcontrib><creatorcontrib>Tang, Wai-Lun</creatorcontrib><creatorcontrib>Poon, Wing-Tat</creatorcontrib><creatorcontrib>Ng, Chi-Fai</creatorcontrib><title>A prospective evaluation of the effect of finasteride on prostate health index (phi)</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><addtitle>Int Urol Nephrol</addtitle><description>Purpose
5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index (
phi
) is unknown. This study aims to investigate this effect and to enable accurate interpretation of
phi
in men with elevated PSA and on 5ARI.
Methods
This is a prospective study evaluating the effect of finasteride on PSA, free PSA (fPSA), [ – 2]proPSA (p2PSA) and
phi
at 6 and 12 moths in men with PSA 4-20 ng/mL, no prior 5ARI use, and one negative prostate biopsy within 6 months before recruitment. The 5ARI Finasteride (5 mg/day) for 1 year was offered if International Prostatic Symptom Score (IPSS) was ≥ 8 at baseline. 5ARI group included patients taking finasteride, while control group included patients not on finasteride. The blood results were compared with
t
-test between baseline and different time points in each group and between groups at 1 year.
Results
164 men fit the inclusion criteria and 150 were analyzed. In 5ARI group (n = 100) at 1 year, mean PSA reduced by 51.4% from 8.9(± SD 3.7) to 4.4(± SD 2.8)ng/mL (paired t-test, p < 0.001), fPSA reduced by 52.4% from 1.6(± 0.6) to 0.8(± 0.4)ng/mL (p < 0.001), p2PSA reduced by 55.3% from 18.4(± 8.8) to 8.3(± 5.6)pg/mL (p < 0.001), and
phi
reduced by 34.2% from 33.7(± 11.9) to 22.4(± 12.5) (p < 0.001). PSA and
phi
values in the control group remained static over 1 year and significantly higher than those in 5ARI group.
Conclusion
This study demonstrated p2PSA and phi are reduced by about 55% and 34% in men on 5ARI. A conversion factor of division by 0.66 is needed for
phi
in men on finasteride to allow the interpretation and use of
phi
in men on 5ARI.</description><subject>Biopsy</subject><subject>Finasteride - pharmacology</subject><subject>Finasteride - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Prospective Studies</subject><subject>Prostate</subject><subject>Prostate - pathology</subject><subject>Prostate cancer</subject><subject>Prostate-Specific Antigen</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Urology</subject><subject>Urology - Original Paper</subject><issn>1573-2584</issn><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kDtPwzAUhS0EoqXwBxhQJJYyBK7tOE7HquIlVWIps-Uk1yRVmoTYqeDf45LyEAOTH-c7x9eHkHMK1xRA3lhKmRAhMB4CFxxCfkDGVEgeMpFEh7_2I3Ji7RoAZgnAMRnxOBHxjIkxWc2Dtmtsi5krtxjgVle9dmVTB40JXOFvjPHa7mTKWluHXZlj4PWdzWmHQYG6ckVQ1jm-BdO2KK9OyZHRlcWz_Tohz3e3q8VDuHy6f1zMl2HGpXAhm8koyQyVElCYmEIOkqNhGMtMiwy1NgB5RBEpS0UmU2ogBY0xFzNBc8EnZDrk-llee7RObUqbYVXpGpveKiYTymjEYunRyz_ouum72k-nWAI0gogz5ik2UJn_nO3QqLYrN7p7VxTUrnM1dK585-qzc8W96WIf3acbzL8tXyV7gA-A9VL9gt3P2__EfgBGY4tn</recordid><startdate>20230501</startdate><enddate>20230501</enddate><creator>Chiu, Peter Ka-Fung</creator><creator>Chan, Chun-Hong</creator><creator>Liu, Alex Qinyang</creator><creator>Lau, Sui-Yan</creator><creator>Leung, Chi-Ho</creator><creator>Chan, Yun-Sang</creator><creator>Yuen, Steffi Kar-Kei</creator><creator>Yee, Chi-Hang</creator><creator>Teoh, Jeremy Yuen-Chun</creator><creator>Tang, Wai-Lun</creator><creator>Poon, Wing-Tat</creator><creator>Ng, Chi-Fai</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-0302-0472</orcidid></search><sort><creationdate>20230501</creationdate><title>A prospective evaluation of the effect of finasteride on prostate health index (phi)</title><author>Chiu, Peter Ka-Fung ; Chan, Chun-Hong ; Liu, Alex Qinyang ; Lau, Sui-Yan ; Leung, Chi-Ho ; Chan, Yun-Sang ; Yuen, Steffi Kar-Kei ; Yee, Chi-Hang ; Teoh, Jeremy Yuen-Chun ; Tang, Wai-Lun ; Poon, Wing-Tat ; Ng, Chi-Fai</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-29748cf1770e5f610d073ef2e67ca5ceaaf00d41ee12b5c7b1f0b0ae635951d53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biopsy</topic><topic>Finasteride - pharmacology</topic><topic>Finasteride - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Prospective Studies</topic><topic>Prostate</topic><topic>Prostate - pathology</topic><topic>Prostate cancer</topic><topic>Prostate-Specific Antigen</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Urology</topic><topic>Urology - Original Paper</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chiu, Peter Ka-Fung</creatorcontrib><creatorcontrib>Chan, Chun-Hong</creatorcontrib><creatorcontrib>Liu, Alex Qinyang</creatorcontrib><creatorcontrib>Lau, Sui-Yan</creatorcontrib><creatorcontrib>Leung, Chi-Ho</creatorcontrib><creatorcontrib>Chan, Yun-Sang</creatorcontrib><creatorcontrib>Yuen, Steffi Kar-Kei</creatorcontrib><creatorcontrib>Yee, Chi-Hang</creatorcontrib><creatorcontrib>Teoh, Jeremy Yuen-Chun</creatorcontrib><creatorcontrib>Tang, Wai-Lun</creatorcontrib><creatorcontrib>Poon, Wing-Tat</creatorcontrib><creatorcontrib>Ng, Chi-Fai</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chiu, Peter Ka-Fung</au><au>Chan, Chun-Hong</au><au>Liu, Alex Qinyang</au><au>Lau, Sui-Yan</au><au>Leung, Chi-Ho</au><au>Chan, Yun-Sang</au><au>Yuen, Steffi Kar-Kei</au><au>Yee, Chi-Hang</au><au>Teoh, Jeremy Yuen-Chun</au><au>Tang, Wai-Lun</au><au>Poon, Wing-Tat</au><au>Ng, Chi-Fai</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A prospective evaluation of the effect of finasteride on prostate health index (phi)</atitle><jtitle>International urology and nephrology</jtitle><stitle>Int Urol Nephrol</stitle><addtitle>Int Urol Nephrol</addtitle><date>2023-05-01</date><risdate>2023</risdate><volume>55</volume><issue>5</issue><spage>1087</spage><epage>1092</epage><pages>1087-1092</pages><issn>1573-2584</issn><issn>0301-1623</issn><eissn>1573-2584</eissn><abstract>Purpose
5-alpha reductase inhibitor (5ARI) reduces prostate-specific antigen (PSA) by half but its effect on prostate health index (
phi
) is unknown. This study aims to investigate this effect and to enable accurate interpretation of
phi
in men with elevated PSA and on 5ARI.
Methods
This is a prospective study evaluating the effect of finasteride on PSA, free PSA (fPSA), [ – 2]proPSA (p2PSA) and
phi
at 6 and 12 moths in men with PSA 4-20 ng/mL, no prior 5ARI use, and one negative prostate biopsy within 6 months before recruitment. The 5ARI Finasteride (5 mg/day) for 1 year was offered if International Prostatic Symptom Score (IPSS) was ≥ 8 at baseline. 5ARI group included patients taking finasteride, while control group included patients not on finasteride. The blood results were compared with
t
-test between baseline and different time points in each group and between groups at 1 year.
Results
164 men fit the inclusion criteria and 150 were analyzed. In 5ARI group (n = 100) at 1 year, mean PSA reduced by 51.4% from 8.9(± SD 3.7) to 4.4(± SD 2.8)ng/mL (paired t-test, p < 0.001), fPSA reduced by 52.4% from 1.6(± 0.6) to 0.8(± 0.4)ng/mL (p < 0.001), p2PSA reduced by 55.3% from 18.4(± 8.8) to 8.3(± 5.6)pg/mL (p < 0.001), and
phi
reduced by 34.2% from 33.7(± 11.9) to 22.4(± 12.5) (p < 0.001). PSA and
phi
values in the control group remained static over 1 year and significantly higher than those in 5ARI group.
Conclusion
This study demonstrated p2PSA and phi are reduced by about 55% and 34% in men on 5ARI. A conversion factor of division by 0.66 is needed for
phi
in men on finasteride to allow the interpretation and use of
phi
in men on 5ARI.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>36856925</pmid><doi>10.1007/s11255-023-03530-3</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-0302-0472</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1573-2584 |
| ispartof | International urology and nephrology, 2023-05, Vol.55 (5), p.1087-1092 |
| issn | 1573-2584 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2781214267 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biopsy Finasteride - pharmacology Finasteride - therapeutic use Humans Male Medicine Medicine & Public Health Nephrology Prospective Studies Prostate Prostate - pathology Prostate cancer Prostate-Specific Antigen Prostatic Neoplasms - pathology Urology Urology - Original Paper |
| title | A prospective evaluation of the effect of finasteride on prostate health index (phi) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T00%3A54%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20prospective%20evaluation%20of%20the%20effect%20of%20finasteride%20on%20prostate%20health%20index%20(phi)&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Chiu,%20Peter%20Ka-Fung&rft.date=2023-05-01&rft.volume=55&rft.issue=5&rft.spage=1087&rft.epage=1092&rft.pages=1087-1092&rft.issn=1573-2584&rft.eissn=1573-2584&rft_id=info:doi/10.1007/s11255-023-03530-3&rft_dat=%3Cproquest_cross%3E2781214267%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2801404322&rft_id=info:pmid/36856925&rfr_iscdi=true |